Lucid Diagnostics Inc.

Lucid Diagnostics Inc.

NNASDAQ:LUCD
0.40
USD
-0.05
(-11.42%)
-0.29EPS
143.42MMarket Cap
Mar 29Next Earn
Lucid Diagnostics Inc.
NASDAQ:LUCD
(Nasdaq Stock Market)

Recent

price

0.40

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
0.03
0.01
0.06
0.09
0.03
0.03
Revenue per Share
-0.12
-0.22
-1.51
-1.55
-1.26
-1.05
-0.43
-0.36
Basic EPS, GAAP
-0.06
-0.15
-1
-0.85
-0.79
-0.89
-0.28
-0.31
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.14
-0.37
1.57
0.57
-0.49
-0.78
-0.33
0.03
Book Value per Share
-0.14
-0.37
1.57
0.48
-0.53
-0.79
-0.33
0.03
Tangible Book Value per Share
37
37
19
36
42
51
164
169
Basic Weighted Avg Shares
- -
- -
1
- -
2
4
5
5
Sales/Revenue/Turnover
- -
- -
-5,483.8
-14,920.69
-1,996.79
-1,059.64
-1,054.82
-941.73
Operating Margin (%)
- -
- -
- -
2
2
1
1
1
Depreciation Expense
-4
-8
-28
-56
-53
-46
-58
-49
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-5,615.6
-14,899.47
-2,169.11
-1,047.61
-1,232.68
-892.75
Profit Margin (%)
-6
-14
53
16
-7
2
9
4
Working Capital
- -
- -
- -
1
- -
2
1
- -
LT Debt
-5
-14
55
23
-2
5
11
6
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-144.42
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
26
24
18
LT Borrowings
- -
- -
- -
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
10
- -
- -
Shares Outstanding
165
191
191
Market Capitalization
190
204
143

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
31
37
26
Cash, Cash Equivalents & STI
28
33
18
Accounts Receivable, Net
1
1
1
Inventories
- -
- -
1
Total Current Liabilities
29
28
22
Payables & Accruals
3
3
3
ST Debt
26
24
18
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-180.66%
102.86%
Free Cash Flow
- -
68.41%
4.23%
Net Income, GAAP
- -
69.36%
27.41%
Sales/Revenue/Turnover
- -
- -
8.28%
Total Cash Common Dividend
- -
- -
67.54%

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
1
1
1
4
2025
1
1
1
2
5
2026
1
1
1
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.4
-0.23
-0.25
-0.2
-1.05
2025
-0.52
-0.08
-0.1
-0.1
-0.43
2026
-0.17
-0.08
-0.03
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Lucid Diagnostics Inc. (Nasdaq: LUCD) is a commercial-stage cancer prevention medical diagnostics company focused on early detection of esophageal precancer and cancer in patients with gastroesophageal reflux disease (GERD). The company offers EsoGuard Esophageal DNA Test, a laboratory developed test (LDT) that detects esophageal precancer using next-generation sequencing on samples collected via the EsoCheck Esophageal Cell Collection Device, a 510(k)-cleared, non-invasive capsule-based tool for in-office esophageal cell collection; it operates LucidDx Labs Inc., a CLIA-certified, CAP-accredited clinical laboratory licensed by the New York State Department of Health. A subsidiary of PAVmed Inc. (Nasdaq: PAVM), Lucid Diagnostics targets at-risk populations including GERD patients and high-risk groups such as firefighters, with U.S.-focused commercialization supported by partnerships with healthcare networks, fire departments, and municipalities for screening programs. Founded in 2018 and headquartered at 360 Madison Avenue, 25th Floor, New York, New York, the company maintains a workforce of approximately 72 employees. Recent developments include a September 2025 public offering of common stock led by Canaccord Genuity as joint bookrunner to strengthen its balance sheet; a partnership with Hoag health system to launch a comprehensive EsoGuard testing program across digestive health, primary care, and concierge medicine; expansion into three new states projecting up to 15% revenue growth; publication of an NCI-sponsored study in the American Journal of Gastroenterology demonstrating EsoGuard's efficacy in non-symptomatic patients, potentially expanding the addressable market by 70%; and progress toward Medicare reimbursement including a Multi-X Contractor Advisory Committee meeting and final payment determination for EsoGuard.

Company News

  • PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

  • What Lucid Diagnostics (LUCD) Said on Its Q3 Earnings Call

  • Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript

  • Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates

  • Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results

  • Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates

  • Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year

  • Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

  • Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study

  • PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026

  • Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026

  • Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing

  • Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways

  • Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth

  • PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

  • Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript

  • Lucid Diagnostics Q2 Earnings Call Highlights

  • Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates

  • Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

  • Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test